Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
:CRDF
CRDF Stock Chart & Stats
$2.28
-$0.21(-4.99%)
At close: 4:00 PM EST
$2.28
-$0.21(-4.99%)
Day’s Range― - ―
52-Week Range$1.90 - $5.64
Previous CloseN/A
Volume446.20K
Average Volume (3M)818.51K
Market Cap
$147.69M
Enterprise ValueN/A
Total Cash (Recent Filing)$70.96M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Feb 26, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding66,525,856
10 Day Avg. Volume705,855
30 Day Avg. Volume818,515
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$10.00Price Target Upside338.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementManagement plans to pursue a Phase III trial with registrational intent (CRDF-005).
Drug EfficacyOnvansertib is clearly active and exhibits an additive effect to the standard of care in mCRC.
Treatment Paradigm DisruptionAnalyst holds a bullish view that onvansertib could hold the potential to disrupt the RAS-mutated frontline mCRC treatment paradigm.
Bears Say
Control Arm PerformanceSome investors have expressed concern that the control arm may be somewhat underperforming expectations.
Funding ConcernsCardiff requires additional capital to conduct the Phase III study.
Investor SkepticismThe current valuation reflects considerable skepticism regarding the compound’s clinical profile.
Cardiff Oncology News
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $1.90 and its highest was $5.64 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Cardiff Oncology, Inc.’s market cap is $147.69M.
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Feb 26, 2026 which is in 110 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.205 by $0.035.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -0.2.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 66,525,856 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.205. Following the earnings report the stock price went up 0.446%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Currently, no hedge funds are holding shares in CRDF
Cardiff Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (338.60% Upside)
$10.00 (338.60% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 134.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $710.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.29%
12-Months-Change
Fundamentals
Return on Equity
-91.93%
Trailing 12-Months
Asset Growth
14.67%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Cardiff Oncology (CRDF) is a clinical-stage biotechnology company focused on developing innovative treatment options for cancer patients. The company primarily operates in the oncology sector, aiming to address unmet medical needs through its novel therapeutics. Cardiff Oncology's core product is onvansertib, an oral and highly selective Polo-like Kinase 1 (PLK1) inhibitor. This drug candidate is being evaluated in clinical trials for various cancer indications, including colorectal cancer, pancreatic cancer, and acute myeloid leukemia.
CRDF Stock 12 Month Forecast
Average Price Target
$10.00
▲(338.60% Upside)
Technical Analysis
Oncolytics Biotech
―
Oncolytics Biotech
―
Avalo Therapeutics
―
Greenwich LifeSciences
―
Molecular Partners
―
Pyxis Oncology
―
Ownership Overview
4.43% Insiders
7.91% Mutual Funds
2.00% Other Institutional Investors
77.38% Public Companies and Individual Investors